Mereo BioPharma Group plc (MREO) — Setrusumab misses both Phase 3 fracture endpoints

What Happened

Clinical readout: On December 29, 2025, Mereo announced that setrusumab (UX143) missed the primary fracture-rate endpoints in both Phase 3 ORBIT and COSMIC studies in osteogenesis imperfecta, weakening the evidence for the program’s potential development and registration path. (1) (2)
Clinical Results Details: Both studies reported statistically significant improvements in bone mineral density (BMD), but neither demonstrated a statistically significant reduction in fractures. In ORBIT, BMD improvements were not accompanied by a corresponding fracture-rate reduction; in pediatric COSMIC, the fracture-rate reduction versus bisphosphonates was not statistically significant. Mereo reported no change in the observed safety profile. (1) (2)

Trading Background

MREO was volatile but modestly higher over the final three clean months before the readout, rising from $2.06 on September 30 to $2.31 on December 26, 2025, about 12%. The broader six-month backdrop was weaker after a 42.5% decline on July 10 following the prior-day ORBIT DMC update that the study would continue to final analysis; immediately before the readout, shares also fell 8.6% on December 17 and rose 14.5% on December 22, with no corresponding Mereo company release identified. The ORBIT/COSMIC results were released at 8:31 a.m. ET on December 29, so December 26 is the last clean pre-trigger close. (3)

Confirmed Information Based on Disclosures

Different study settings: ORBIT was a seamless Phase 2/3 study with a pivotal Phase 3 portion, testing setrusumab against placebo in patients aged 5 to 25 years. COSMIC was a separate Phase 3 study in children aged 2 to under 7 years, comparing setrusumab with intravenous bisphosphonates; the populations and comparators differ. (1) (4) (5)
Partner structure and conditional economics: Ultragenyx funds and leads global setrusumab development. Mereo retains EU and UK commercial rights and may receive additional milestone payments of up to $245 million and royalties on sales in Ultragenyx territories, subject to contractual triggers and subsequent outcomes. (1) (6)
Company financial baseline: Mereo reported $48.7 million in cash at September 30, 2025. Management had expected that cash to fund currently committed trials, operating expenses and capital expenditures into 2027 under then-current plans; that projection did not cover all future development or commercialization. Mereo had no approved products or product-sales revenue. (7)

Key Missing Information

Whether a credible pediatric fracture hypothesis survives: Both Phase 3 trials did not meet their primary endpoints, suggesting a narrower development or regulatory path for any future development. However, full fracture and BMD effect estimates, event counts and statistical context have not been disclosed, so the possibility of further development cannot be ruled out. Mereo has not given a timing for its further analyses or a program decision. (1) (2)
Partner continuation and Mereo’s future economic exposure: No post-readout Ultragenyx continuation decision, regulator feedback or assessment of applicable milestone triggers has been disclosed. Under the existing collaboration, Ultragenyx pays all global development costs; accordingly, the unresolved questions are whether Ultragenyx continues the program and how continuation or discontinuation affects Mereo’s milestone, royalty and EU/UK commercial economics. (1) (6)
Scope of the operating reductions and revised cash plan: Mereo has not specified which programs or regions are affected by the pre-commercial and manufacturing reductions, their scale or duration, or an updated operating plan and cash forecast. As a result, investors cannot assess the reductions’ effect on setrusumab’s regional preparation or on the company’s cash horizon. (1) (7)

Company's Response

Mereo said it is conducting additional analyses across both studies, including bone-health and clinical endpoints beyond fractures, to assess next steps, particularly in pediatrics; it has not announced a program decision or timing. The company announced immediate reductions in pre-commercial and manufacturing activities while managing cash resources, without specifying their program or regional scope. It also said it would continue advancing partnering discussions for alvelestat. (1) (2)

News Release Framing Risks

The COSMIC discussion describes “meaningful improvements in BMD” associated with a fracture-rate reduction before stating that the reduction was not statistically significant. Although the release also reports that the primary endpoint was not achieved, this ordering may give the directional pediatric result more weight than the evidence supports; the size and uncertainty of the difference remain undisclosed. (1)

Analytical Interpretation

Pre-event expectation snapshot: Immediately before the readout, Mereo expected year-end 2025 data from distinct late-stage studies testing setrusumab’s effect on fracture rates against placebo in ORBIT and intravenous bisphosphonates in pediatric COSMIC, with no disclosed efficacy forecast and further development conditional on the results. (3)
Post-event change of expectation: Both studies missed their primary fracture-rate endpoints, materially weakening the conditional development and registration path; positive BMD findings and Mereo’s planned further analyses leave the program direction unresolved. (1)
Integrated assessment:
- The central proposition—that setrusumab would demonstrate fracture reduction against each study’s comparator—was not established in either setting. Results across two distinct studies weaken the broad late-stage fracture-benefit case, while remaining bounded to the populations and designs tested. (1)
- BMD improvements preserve evidence of biological activity, but do not establish fracture benefit or reverse either primary result. COSMIC’s nonsignificant fracture-rate direction is hypothesis-generating; the low placebo fracture rate reported in ORBIT may have limited separation there, but is not an established cause and does not explain COSMIC’s result. (1)
- The immediate path is analysis of existing data, which may refine the evidence and clarify whether a pediatric hypothesis remains credible; it cannot by itself reverse the reported primary results. A prospective randomized pediatric fracture-efficacy study is conditional on that review and regulator engagement, and would require protocol and site preparation, enrollment, treatment and fracture-event accrual, follow-up, analysis and review. Such a study would carry very high time and operational burden; the existing program’s treatment requirement of at least 18 months is a historical scale anchor, not a forecast for a future study. (1) (3)
- The missed endpoints weaken the potential registration path and Mereo’s conditional EU/UK commercial opportunity. The announced reductions in pre-commercial and manufacturing activity may limit near-term outlays, but their setrusumab-specific effect is unclear; no filing change, launch cancellation or program termination has been announced. (1) (6) (7)
- The principal economic damage is to prospective growth, not current product revenue: Mereo had no product-sales base, while its potential EU/UK sales and contingent milestone and royalty economics in Ultragenyx territories are less secure. Under the existing collaboration, Ultragenyx pays all global development costs, so a new global clinical study would not create an established Mereo clinical-development funding obligation unless that arrangement changed. Mereo’s reported cash and then-current-plan horizon supported the near-term analysis and decision process and Mereo’s own operating and commercial obligations, not broader commercialization. (1) (6) (7)
- Setrusumab’s weaker path increases alvelestat’s relative importance to Mereo’s prospective trajectory, but no clinical read-through, improved probability or resource transfer is established; Mereo said alvelestat partnering discussions would continue. The next sequence is full-data review, a Mereo/Ultragenyx continuation decision and any regulator feedback, then—only if further testing is proposed—agreement on study requirements under the existing collaboration. (1) (7)
- Overall implication of this event: Mereo moves from a pre-commercial company with a partnered late-stage setrusumab opportunity to one with a materially weakened conditional growth path and disclosed operating reductions; its trajectory now depends on whether full-data review supports a credible pediatric path, whether Ultragenyx continues the program under the existing development-funding arrangement, and how any further development would affect Mereo’s contingent economics and EU/UK commercial obligations. (1) (6) (7)